

Christopher J Hoimes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1906965/publications.pdf>

Version: 2024-02-01

55
papers

3,447
citations

236925

25
h-index

206112

48
g-index

57
all docs

57
docs citations

57
times ranked

6084
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma. JAMA Oncology, 2017, 3, e172411.	7.1	750
2	Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. Journal of Clinical Oncology, 2020, 38, 395-405.	1.6	450
3	Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 1240-1267.	4.9	220
4	A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. Clinical Cancer Research, 2019, 25, 43-51.	7.0	177
5	NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 1041-1053.	4.9	171
6	Targeted nanotechnology for cancer imaging. Advanced Drug Delivery Reviews, 2014, 76, 79-97.	13.7	160
7	Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial. , 2018, 6, 111.		122
8	The effect of hyperbranched polyglycerol coatings on drug delivery using degradable polymer nanoparticles. Biomaterials, 2014, 35, 6595-6602.	11.4	121
9	Characteristics and Survival of Malignant Cardiac Tumors. Circulation, 2015, 132, 2395-2402.	1.6	117
10	Radiomics Analysis on FLT-PET/MRI for Characterization of Early Treatment Response in Renal Cell Carcinoma: A Proof-of-Concept Study. Translational Oncology, 2016, 9, 155-162.	3.7	94
11	NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1213-1224.	4.9	93
12	Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. Cancer, 2018, 124, 2115-2124.	4.1	79
13	Surface modified poly(β 2 amino ester)-containing nanoparticles for plasmid DNA delivery. Journal of Controlled Release, 2012, 164, 41-48.	9.9	75
14	Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer. JAMA Oncology, 2021, 7, 1856.	7.1	74
15	Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. Cancer, 2020, 126, 1208-1216.	4.1	70
16	Treatment of Invasive Brain Tumors Using a Chain-like Nanoparticle. Cancer Research, 2015, 75, 1356-1365.	0.9	63
17	Nanoparticle Encapsulation of Synergistic Immune Agonists Enables Systemic Codelivery to Tumor Sites and IFN γ -Driven Antitumor Immunity. Cancer Research, 2019, 79, 5394-5406.	0.9	55
18	Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer. Nanomedicine: Nanotechnology, Biology, and Medicine, 2013, 9, 1124-1134.	3.3	51

#	ARTICLE	IF	CITATIONS
19	Redefining hormone resistance in prostate cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2010, 2, 107-123.	3.2	41
20	A phase 1 trial of SGNâ€CD70A in patients with CD70â€positive, metastatic renal cell carcinoma. <i>Cancer</i> , 2019, 125, 1124-1132.	4.1	41
21	Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 405-412.	1.6	40
22	A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. <i>European Urology Oncology</i> , 2021, 4, 464-472.	5.4	39
23	Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2). <i>British Journal of Cancer</i> , 2018, 118, 1434-1441.	6.4	34
24	Immune checkpoint-mediated myositis and myasthenia gravis: A case report and review of evaluation and management. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2018, 39, 642-645.	1.3	33
25	Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study. <i>Journal of Urology</i> , 2020, 204, 63-70.	0.4	32
26	Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4525-4525.	1.6	30
27	Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance). <i>Journal of Clinical Oncology</i> , 2021, 39, 2486-2496.	1.6	26
28	Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma. <i>Targeted Oncology</i> , 2018, 13, 599-609.	3.6	22
29	Racial Disparities in Partial Nephrectomy Persist Across Hospital Types: Results From a Population-based Cohort. <i>Urology</i> , 2016, 90, 69-75.	1.0	18
30	Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. <i>BJU International</i> , 2021, 128, 196-205.	2.5	18
31	Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors: ARTISTRY-1.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2500-2500.	1.6	17
32	Small Molecule-Based Prodrug Targeting Prostate Specific Membrane Antigen for the Treatment of Prostate Cancer. <i>Cancers</i> , 2021, 13, 417.	3.7	16
33	Hodgkin's Lymphoma of the Breast. <i>Journal of Clinical Oncology</i> , 2010, 28, e11-e13.	1.6	15
34	Myocarditis associated with immune checkpoint inhibitor therapy: a case report of three patients. <i>Emergency Radiology</i> , 2020, 27, 455-460.	1.8	10
35	Imaging and clinical manifestations of immune checkpoint inhibitor-related colitis in cancer patients treated with monotherapy or combination therapy. <i>Abdominal Radiology</i> , 2020, 45, 3028-3035.	2.1	9
36	Immunological correlates of response to immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (mUC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2018, 36, 454-454.	1.6	9

#	ARTICLE	IF	CITATIONS
37	Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy.. Journal of Clinical Oncology, 2018, 36, 9513-9513.	1.6	6
38	Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients with muscle-invasive bladder cancer who are cisplatin-ineligible.. Journal of Clinical Oncology, 2022, 40, 4582-4582.	1.6	6
39	A phase I trial of ALKS 4230, an engineered cytokine activator of NK and effector T cells, in patients with advanced solid tumors.. Journal of Clinical Oncology, 2017, 35, TPS3111-TPS3111.	1.6	5
40	EV-103 study: A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer.. Journal of Clinical Oncology, 2018, 36, TPS532-TPS532.	1.6	5
41	Early Response Monitoring of Receptor Tyrosine Kinase Inhibitor Therapy in Metastatic Renal Cell Carcinoma Using [F-18]Fluorothymidine-Positron Emission Tomography-Magnetic Resonance. Seminars in Roentgenology, 2014, 49, 238-241.	0.6	4
42	Clinical, Imaging Findings, Responses, and Outcomes of Patients With Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma Undergoing Immune Checkpoint Inhibitor Therapy: A Single-Institution Experience. Journal of Computer Assisted Tomography, 2020, 44, 619-626.	0.9	4
43	Evaluation of the spectrum selective RTK inhibitor sitravatinib in clear cell renal cell carcinoma (ccRCC) refractory to anti-angiogenic therapy (AAT).. Journal of Clinical Oncology, 2018, 36, 4568-4568.	1.6	4
44	Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin. Clinical Genitourinary Cancer, 2022, 20, 165-175.	1.9	4
45	High-dose interleukin-2 therapy related adverse events and implications on imaging. , 2021, 27, 684-689.		3
46	Association of prior local therapy and outcomes with programmed death ligand-1 inhibitors in advanced urothelial cancer. BJU International, 2022, 130, 592-603.	2.5	3
47	Editorial Comment. Urology, 2016, 88, 132-133.	1.0	2
48	Circulating tumor (ct)-DNA alterations in urothelial/bladder cancer (UC/BC): Updates on a dynamic genomic landscape.. Journal of Clinical Oncology, 2017, 35, 4534-4534.	1.6	2
49	Systemic Therapies for Melanoma Brain Metastases. Journal of Computer Assisted Tomography, 2020, 44, 346-355.	0.9	1
50	Serial measurements of myeloid derived suppressor cells (MDSC) in metastatic urothelial carcinoma (mUC) patients (pts) treated with immune checkpoint inhibitors (CI).. Journal of Clinical Oncology, 2017, 35, e16005-e16005.	1.6	1
51	TROC 96.01: TTFB and PSAdt as surrogates for disease specific mortality. Update on Cancer Therapeutics, 2009, 3, 157-159.	0.4	0
52	Myeloid derived suppressor cells (MDSC) and inflammatory biomarkers in metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology, 2017, 35, 4548-4548.	1.6	0
53	Outcomes in bone predominant (BP) urothelial carcinoma (UC).. Journal of Clinical Oncology, 2018, 36, 441-441.	1.6	0
54	Serial changes in PD1/PDL1 expression in metastatic urothelial carcinoma (mUC) patients (pts) treated with immune checkpoint blockade (CPB).. Journal of Clinical Oncology, 2018, 36, 109-109.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Patterns of metastases, treatment (tx), and outcomes in bone predominant (BP) metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology, 2018, 36, e16523-e16523.	1.6	0